{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:26:23Z","timestamp":1788215183596,"version":"build-2803163510"},"reference-count":28,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2022,12,1]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Question<\/jats:title>\n                    <jats:p>Are antipsychotic dose equivalents between acute mania and schizophrenia the same?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection and analysis<\/jats:title>\n                    <jats:p>Six databases were systematically searched (from inception to 17 September 2022) to identify blinded randomised controlled trials (RCTs) that used a flexible-dose oral antipsychotic drug for patients with acute mania. The mean and SD of the effective dose and the pre\u2013post changes in manic symptoms were extracted. A network meta-analysis (NMA) under a frequentist framework was performed to examine the comparative efficacy between the antipsychotics. A classic mean dose method (sample size weighted) was used to calculate each antipsychotic dose equivalent to 1\u2009mg\/day olanzapine for acute mania. The antipsychotic dose equivalents of acute mania were compared with published data for schizophrenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>We included 42 RCTs which enrolled 11\u2009396 participants with acute mania. The NMA showed that risperidone was superior to olanzapine (reported standardised mean difference: \u2212022, 95% CI \u22120.41 to \u20130.02), while brexpiprazole was inferior to olanzapine (standardised mean difference: 0.36, 95% CI 0.08 to 0.64). The dose equivalents to olanzapine (with SD) were 0.68 (0.23) for haloperidol, 0.32 (0.07) for risperidone, 0.60 (0.11) for paliperidone, 8.00 (1.41) for ziprasidone, 41.46 (5.98) for quetiapine, 1.65 (0.32) for aripiprazole, 1.23 (0.20) for asenapine, 0.53 (0.14) for cariprazine and 0.22 (0.03) for brexpiprazole. Compared with the olanzapine dose equivalents for schizophrenia, those of acute mania were higher for quetiapine (p&lt;0.001, 28.5%) and aripiprazole (p&lt;0.001, 17.0%), but lower for haloperidol (p&lt;0.001, \u20138.1%) and risperidone (p&lt;0.001, \u201315.8%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Antipsychotic drugs have been considered first-line treatment for acute mania, warranting specific dose equivalence for scientific and clinical purposes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjment-2022-300546","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T10:50:24Z","timestamp":1675767024000},"page":"e300546","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia"],"prefix":"10.1136","volume":"26","author":[{"given":"Chia-Ling","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Chang Gung Memorial Hospital Linkou, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre F","family":"Carvalho","sequence":"additional","affiliation":[{"name":"IMPACT (Innovation in Mental and Physical Health and Clinical Treatment) Strategic Research Centre, School of Medicine, Deakin University, Geelong, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Thompson","sequence":"additional","affiliation":[{"name":"Centre for Chronic Illness and Ageing, University of Greenwich, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Cheng","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chang Gung Memorial Hospital Linkou, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5761-7800","authenticated-orcid":false,"given":"Ping-Tao","family":"Tseng","sequence":"additional","affiliation":[{"name":"Prospect Clinic for Otorhinolaryngology & Neurology, Kaohsiung City, Taiwan"},{"name":"Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan"},{"name":"Department of Psychology, College of Medical and Health Science, Asia University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8650-4060","authenticated-orcid":false,"given":"Chih-Wei","family":"Hsu","sequence":"additional","affiliation":[{"name":"Deaparment of Psychiatry, Chang Gung Memorial Hospital Kaohsiung Branch, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Wei","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1138-5586","authenticated-orcid":false,"given":"Chih-Sung","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"2025082623522430000_26.1.e300546.1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41380-021-01334-4","article-title":"Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials","volume":"27","author":"Kishi","year":"2022","journal-title":"Mol Psychiatry"},{"key":"2025082623522430000_26.1.e300546.2","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12609"},{"key":"2025082623522430000_26.1.e300546.3","unstructured":"NICE . Bipolar disorder: the NICE guideline on the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. London, 2014."},{"key":"2025082623522430000_26.1.e300546.4","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.13036"},{"key":"2025082623522430000_26.1.e300546.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2015.03.021"},{"key":"2025082623522430000_26.1.e300546.6","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbv037"},{"key":"2025082623522430000_26.1.e300546.7","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(74)90071-5"},{"key":"2025082623522430000_26.1.e300546.8","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.1.1"},{"key":"2025082623522430000_26.1.e300546.9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4088\/JCP.v61n0116","article-title":"High exposure to neuroleptics in bipolar patients: a retrospective review","volume":"61","author":"Brotman","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"2025082623522430000_26.1.e300546.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1614.2004.01340.x"},{"key":"2025082623522430000_26.1.e300546.11","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12906"},{"key":"2025082623522430000_26.1.e300546.12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"2025082623522430000_26.1.e300546.13","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"2025082623522430000_26.1.e300546.14","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2009.09060802"},{"key":"2025082623522430000_26.1.e300546.15","doi-asserted-by":"publisher","DOI":"10.1177\/0145445516673998"},{"key":"2025082623522430000_26.1.e300546.16","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2025082623522430000_26.1.e300546.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-018-0483-0","article-title":"Dealing with missing standard deviation and mean values in meta-analysis of continuous outcomes: a systematic review","volume":"18","author":"Weir","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"2025082623522430000_26.1.e300546.18","doi-asserted-by":"publisher","DOI":"10.1177\/0962280216669183"},{"key":"2025082623522430000_26.1.e300546.19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2025082623522430000_26.1.e300546.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2025082623522430000_26.1.e300546.21","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.741"},{"key":"2025082623522430000_26.1.e300546.22","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000169068.34322.70"},{"key":"2025082623522430000_26.1.e300546.23","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108099418"},{"key":"2025082623522430000_26.1.e300546.24","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbu001"},{"key":"2025082623522430000_26.1.e300546.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.06.030"},{"key":"2025082623522430000_26.1.e300546.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2009.08.040"},{"issue":"Suppl 1","key":"2025082623522430000_26.1.e300546.27","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: the DDD method","volume":"42 Suppl 1","author":"Leucht","year":"2016","journal-title":"Schizophr Bull"},{"key":"2025082623522430000_26.1.e300546.28","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19010034"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2022-300546","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:52:33Z","timestamp":1756277553000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2022-300546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,2,7]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/bmjment-2022-300546"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2022-300546","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}